| Literature DB >> 34744099 |
Xuewei Xie1,2,3,4, Jing Jing1,2,3,4,5, Xia Meng1,2,3,4, Zixiao Li1,2,3,4, Pan Chen1,2,3,4, Xingquan Zhao1,2,3,4, Yilong Wang1,2,3,4, Liping Liu1,2,3,4, Yong Jiang1,2,3,4, Yuesong Pan1,2,3,4, Aoming Jin1,2,3,4, Hao Li1,2,3,4, Yongjun Wang1,2,3,4,5.
Abstract
AIMS: We aimed to validate the predictive value of the ABCD3-I score for short-term and long-term stroke risk after transient ischemic attack (TIA) and to evaluate the influence of symptomatic intracranial artery stenosis (sICAS) on the performance of ABCD3-I.Entities:
Keywords: ABCD3-I; Intracranial artery stenosis; Risk prediction; Stroke incidence; Transient ischemic attack
Mesh:
Year: 2021 PMID: 34744099 PMCID: PMC9444691 DOI: 10.5551/jat.63050
Source DB: PubMed Journal: J Atheroscler Thromb ISSN: 1340-3478 Impact factor: 4.394
Demographic and clinicalcharacteristics
|
Inclusion |
Exclusion | ||
|---|---|---|---|
| Median age (IQR) — yr | 62.0 (53.0-70.0) | 65.0 (56.0-72.0) | 0.01 |
| Male sex - no. (%) | 646 (65.5) | 172 (66.4) | 0.52 |
| Median days from event to enrolment (IQR) | 1.0 (1.0-3.0) | 2.0 (1.0-4.0) | 0.03 |
| Medical history - no. (%) | |||
| Hypertension | 570 (57.8) | 118 (59.6) | 0.64 |
| Diabetes | 173 (17.5) | 53 (26.8) | 0.003 |
| Dyslipidemia | 117 (11.9) | 19 (9.6) | 0.36 |
| Current smoker | 267 (27.1) | 56 (28.3) | 0.73 |
| Current drinker | 141 (14.3) | 26 (13.1) | 0.67 |
| Stroke | 197 (20.0) | 35 (17.7) | 0.46 |
| TIA | 116 (11.8) | 15 (7.6) | 0.09 |
| Coronary artery disease | 118 (12.0) | 24 (12.1) | 0.95 |
| Heart failure | 2 (0.2) | 0 (0.0) | 0.53 |
| Atrial fibrillation | 46 (4.7) | 7 (3.5) | 0.48 |
| Peripheral artery disease | 13 (1.3) | 2 (1.0) | 0.72 |
| Modified Rankin score before admission - no. (%) | 0.54 | ||
| 0 | 805 (81.6) | 168 (84.8) | |
| 1 | 153 (15.5) | 25 (12.6) | |
| Body-mass index (IQR) | 24.6 (22.9-26.7) | 24.8 (23.4-26.6) | 0.49 |
| Blood pressure - mm Hg | |||
| Systolic | 142.0 (130.0-157.5) | 140.0 (130.0-157.5) | 0.37 |
| Diastolic | 83.5 (77.5-91.5) | 81.0 (77.0-90.0) | 0.35 |
| Medication use at discharge - no. (%) | |||
| Antiplatelet agent | 875 (88.7) | 165 (83.3) | 0.03 |
| Lipid-lowering agent | 869 (88.1) | 167 (84.3) | 0.14 |
| Anticoagulant agent | 26 (2.6) | 2 (1.0) | 0.17 |
| Antihypertensive agent | 432 (43.8) | 81 (40.9) | 0.45 |
sICAS indicates symptomatic intracranial stenosis and TIA, transient ischemic attack.
Demographic and clinical characteristics
|
Total |
With ICAS |
Without ICAS | ||
|---|---|---|---|---|
| Median age (IQR) — yr | 62.0 (53.0–70.0) | 65.0 (56.0–72.0) | 61.0 (52.0–68.0) | |
| Male sex- no. (%) | 646 (65.5) | 172 (66.4) | 474 (65.2) | 0.73 |
| Median days event to enrolment (IQR) | 1.0 (1.0–3.0) | 1.0 (1.0–3.0) | 1.0 (1.0–3.0) | 0.4 |
| ABCD3-I | <0.001 | |||
| 0 to 3 | 313 (31.7) | 53 (20.5) | 260 (35.8) | |
| 4 to 7 | 616 (62.5) | 189 (73.0) | 427 (58.7) | |
| 8 to 13 | 57 (5.8) | 17 (6.6) | 40 (5.5) | |
| Medical history - no. (%) | ||||
| Hypertension | 570 (57.8) | 176 (68.0) | 394 (54.2) | <0.001 |
| Diabetes | 173 (17.5) | 54 (20.8) | 119 (16.4) | 0.1 |
| Dyslipidemia | 117 (11.9) | 27 (10.4) | 90 (12.4) | 0.4 |
| Current smoker | 267 (27.1) | 63 (24.3) | 204 (28.1) | 0.25 |
| Current drinker | 141 (14.3) | 30 (11.6) | 111 (15.3) | 0.15 |
| Stroke | 197 (20.0) | 70 (27.0) | 127 (17.5) | 0.001 |
| TIA | 116 (11.8) | 38 (14.7) | 78 (10.7) | 0.09 |
| Coronary artery disease | 118 (12.0) | 39 (15.1) | 79 (10.9) | 0.07 |
| Heart failure | 2 (0.2) | 1 (0.4) | 1 (0.1) | 0.46 |
| Atrial fibrillation | 46 (4.7) | 15 (5.8) | 31 (4.3) | 0.32 |
| Peripheral artery disease | 13 (1.3) | 4 (1.5) | 9 (1.2) | 0.75 |
| Modified Rankin score before admission - no. (%) | 0.16 | |||
| 0 | 805 (81.6) | 203 (78.4) | 602 (82.8) | |
| 1 | 153 (15.5) | 47 (18.1) | 106 (14.6) | |
| Body-mass index (IQR) | 24.6 (22.9–26.7) | 24.8 (22.5–26.9) | 24.6 (22.9–26.7) | 0.82 |
| Blood pressure - mm Hg | ||||
| Systolic | 142.0 (130.0–157.5) | 145.0 (130.0–160.0) | 141.0 (130.0–156.0) | 0.05 |
| Diastolic | 83.5 (77.5–91.5) | 82.5 (76.5–91.0) | 84.0 (78.0–92.0) | 0.12 |
| Medication use at discharge - no. (%) | ||||
| Antiplatelet agent | 875 (88.7) | 236 (91.1) | 639 (87.9) | 0.16 |
| Lipid-lowering agent | 869 (88.1) | 240 (92.7) | 629 (86.5) | 0.009 |
| Anticoagulant agent | 26 (2.6) | 8 (3.1) | 18 (2.5) | 0.6 |
| Antihypertensive agent | 432 (43.8) | 130 (50.2) | 302 (41.5) | 0.02 |
sICAS indicates symptomatic intracranial stenosis and TIA, transient ischemic attack.
Fig.2.Stroke incidence after transient ischemic attack (TIA)
Predictive accuracy of ABCD3-I for stroke risk at different time points of follow-up and in different population
| Stroke Incidence | AUC value | ||
|---|---|---|---|
| Total | sICAS | sICAS free | |
| 14-Day | 0.786 (0.718, 0.855) | 0.774 (0.614, 0.933) | 0.789 (0.710, 0.868) |
| 3-Month | 0.732 (0.658, 0.807) | 0.690 (0.537, 0.844) | 0.748 (0.663, 0.833) |
| 6-Month | 0.715 (0.649, 0.781) | 0.617 (0.488, 0.747) | 0.758 (0.684, 0.833) |
| 12-Month | 0.699 (0.640, 0.758) | 0.611 (0.489, 0.732) | 0.734 (0.669, 0.799) |
AUC indicates area under the curve and sICAS, symptomatic intracranial stenosis
Multivariable-adjusted odds ratios for stroke after TIA at different time points of follow-up
| Odds Ratios (95% CI) |
Interaction value | ||
|---|---|---|---|
| sICAS | sICAS free | ||
| 14-day | 0.0621 | ||
| ABCD3-I(4–7) * | NA | 14.74 (1.98, 109.83) | |
| ABCD3-I(8–13)* | NA | 21 (2.13, 207.19) | |
| 3-month | 0.0079 | ||
| ABCD3-I(4–7)* | 1.28 (0.27, 6.09) | 8.71 (2.05, 36.93) | |
| ABCD3-I(8–13)* | 17.85 (3.22, 98.83) | 10.46 (1.69, 64.69) | |
| 6-month | 0.0285 | ||
| ABCD3-I(4–7)* | 1.44 (0.4, 5.16) | 10.45 (2.48, 43.98) | |
| ABCD3-I(8–13)* | 11.67 (2.57, 52.99) | 18.43 (3.44, 98.62) | |
| 12-month | 0.0294 | ||
| ABCD3-I(4–7)* | 1.44 (0.4, 5.16) | 5.56 (2.17, 14.25) | |
| ABCD3-I(8–13)* | 8.58 (2.11, 34.92) | 9 (2.61, 31.09) | |
| 14-day | 0.0618 | ||
| ABCD3-I (4–7)* | NA | 16.66 (2.23, 124.5) | |
| ABCD3-I (8–13)* | NA | 28.21 (2.8, 284.37) | |
| 3-month | 0.0098 | ||
| ABCD3-I (4–7)* | 1.12 (0.23, 5.45) | 9.67 (2.27, 41.17) | |
| ABCD3-I (8–13)* | 15.37 (2.71, 87.06) | 13.21 (2.09, 83.39) | |
| 6-month | 0.0318 | ||
| ABCD3-I (4–7)* | 1.22 (0.33, 4.48) | 11.52 (2.73, 48.65) | |
| ABCD3-I (8–13)* | 10.67 (2.29, 49.83) | 22.78 (4.17, 124.32) | |
| 12-month | 0.0311 | ||
| ABCD3-I (4–7)* | 1.01 (0.32, 3.2) | 5.81 (2.26, 14.94) | |
| ABCD3-I (8–13)* | 8.08 (1.92, 34) | 9.68 (2.76, 33.89) | |
*Compared with low-risk category ABCD3-I (0–3) Age and gender were adjusted in adjusted model
CI indicates confidence interval and sICAS, symptomatic intracranial stenosis
Baseline characteristics of patients with and without MRI exam in CNSR-III
| Characteristics |
With MRI ( |
Without MRI ( | |
|---|---|---|---|
| Age - year | 62.3±11.2 | 61.6±11.8 | 0.01 |
| Male sex - no. (%) | 8890 (68.3) | 1474 (68.4) | 0.92 |
| Interval from onset to enrolment - day | 2.3±2.0 | 2.4±2.5 | 0.56 |
| ABCD2 (for TIA patients) | 4.2±1.3 | 3.1±1.8 | <0.001 |
| NIHSS (for MIS patients) | 4.2±4.1 | 4.3±4.6 | 0.50 |
| Medical history - no. (%) | |||
| Hypertension | 8167 (62.8) | 1327 (61.6) | 0.30 |
| Diabetes | 2964 (22.8) | 546 (25.3) | 0.009 |
| Dyslipidemia | 1024 (7.9) | 167 (7.8) | 0.85 |
| Current smoker | 4097 (31.5) | 655 (30.4) | 0.32 |
| Current drinker | 1827 (14.0) | 299 (13.9) | 0.84 |
| Stroke | 2850 (21.9) | 505 (23.4) | 0.11 |
| TIA | 355 (2.7) | 61 (2.8) | 0.78 |
| Coronary artery disease | 1315 (10.1) | 293 (13.6) | <0.001 |
| Heart failure | 80 (4.6) | 14 (3.6) | 0.40 |
| Atrial fibrillation | 856 (6.6) | 163 (7.6) | 0.09 |
| Peripheral artery disease | 98 (0.8) | 20 (0.9) | 0.39 |
| mRS before admission - no. (%) | 0.81 | ||
| 0 | 9647 (74.1) | 1600 (74.3) | |
| 1 | 2224 (17.1) | 351 (16.3) | |
| Body-mass index | 24.7±3.4 | 24.7±3.2 | 0.82 |
| Blood pressure - mm Hg | |||
| Systolic | 150.2±22.1 | 149.5±22.0 | 0.09 |
| Diastolic | 87.4±13.1 | 87.0±13.1 | 0.15 |
| TOAST classification - no. (%) | <0.001 | ||
| Large-artery atherosclerosis | 3431 (26.4) | 425 (19.7) | |
| Small-artery occlusion | 2968 (22.8) | 197 (9.1) | |
| Cardioembolism | 768 (5.9) | 149 (6.9) | |
| Other determined etiology | 174 (1.3) | 8 (0.4) | |
| Undetermined etiology | 5671 (43.6) | 1375 (63.8) | |
| Medication use at discharge - no. (%) | |||
| Antiplatelet agent | 11818 (91.0) | 1893 (88.4) | <0.001 |
| Lipid-lowering agent | 11908 (91.7) | 1923 (89.8) | 0.005 |
| Anticoagulant agent | 362 (2.8) | 87 (4.1) | 0.001 |
| Antihypertensive agent | 6383 (49.1) | 1035 (48.3) | 0.49 |
MRI, Magnetic Resonance Imaging; DWI, Diffusion-Weighted Imaging; TIA, transient ischemic attack; MIS, minor ischemic stroke; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NIHSS, National Institute of Health Stroke Scale; TOAST classification: The Trial of Org 10172 in Acute Stroke Treatment classification indicates the probable cause of the index TIA/MIS, including five categories, large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined cause, and undetermined cause; ABCD2, a score (0-7 points) to predict stroke risk following a TIA, including age ≥ 60 years (1 point), blood pressure ≥ 140/90 mm
Hg (1 point), symptoms of unilateral weakness or speech impairment (1-2 points), duration of symptoms of <10 to 59 minutes or ≥ 60
minutes (1-2 points), and diabetes (1 point).
*Values are expressed as means±SD or number (%).